We read with interest the recent paper by Bredenoord et al ,1 in which the authors performed a subgroup analysis of a phase 3 study of dupilumab 300 mg once a week (LIBERTY EoE TREET) showing that dupilumab was effective and well tolerated in patients with eosinophilic oesophagitis (EoE) regardless of prior topical corticosteroids (TCs) use or inadequate response, intolerance and/or contraindication (inadequate/intolerance/contraindication) to TCs. In this regard, it has also been shown that prior treatment with off-label TCs can have an impact on the response to proton pump inhibitors (PPIs) in EoE,2 while evidence on whether prior failure to respond to PPIs or off-label TCs impacts on medical or dietary second-line treatments is conflicting.3 4 The results of Bredenoord et al 1 are positive and reassuring for practitioners but deserve a critical appraisal. In our recent systematic review with network meta-analysis,5 dupilumab 300 mg once a week for 24 …

中文翻译：

---

Dupilumab 对既往外用类固醇暴露患者的疗效：面临嗜酸性粒细胞性食管炎二线治疗


我们饶有兴趣地阅读了 Breenoord 等人最近发表的论文 1，其中作者对每周一次 300 mg dupilumab 的 3 期研究进行了亚组分析 (LIBERTY EoE TREET)，结果表明 dupilumab 在嗜酸性粒细胞增多症患者中有效且耐受性良好无论先前是否使用过外用皮质类固醇 (TC) 或对 TC 反应不足、不耐受和/或禁忌症（不充分/不耐受/禁忌症），食管炎 (EoE) 都会发生。在这方面，还表明，先前使用标签外 TC 治疗可能会对 EoE 中质子泵抑制剂 (PPI) 的反应产生影响，2 同时证明先前是否对 PPI 或标签外 TC 没有反应对医疗或饮食二线治疗的影响是相互矛盾的。3 4 Breenoord 等人 1 的结果是积极的，对从业者来说令人放心，但值得严格评估。在我们最近的网络荟萃分析系统综述中，5 dupilumab 300 mg 每周一次，持续 24 次……